ArticleCureus2026
Comparing IL-6 and IL-10 Serum Levels and Changes Using Propofol and Remimazolam: A Prospective Randomized Controlled Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical stress alters cytokine concentrations, triggering systemic inflammatory responses and immune defense mechanisms. Interleukin-6 (IL-6) and interleukin-10 (IL-10) play important roles in perioperative inflammatory responses. General anesthetics have been shown to affect immune function during surgery. Propofol modulates inflammation by decreasing IL-6, IL-10, and tumor necrosis factor-alpha (TNF-α) levels. Remimazolam, a new ultra-short-acting benzodiazepine, is increasingly used as an induction and maintenance anesthetic agent. However, the effects of remimazolam on inflammatory cytokines and perioperative hemodynamic variables remain unclear.
methodsThis prospective randomized study included 46 patients undergoing total laparoscopic hysterectomy or laparoscopic myomectomy under total intravenous anesthesia. Blood samples were collected at four time points: before anesthesia (T0), at the end of surgery (T1), 1.5 h after surgery (T2), and 24 h after surgery (T3). Serum IL-6, IL-10, and TNF-α levels were measured using enzyme-linked immunosorbent assays. However, TNF-α values were below the detectable range of the assay and were therefore excluded from meaningful statistical analysis.
resultsNo significant intergroup differences were observed in IL-6 or IL-10 levels (F(2.10, 90.08) = 2.43, P = 0.092; F(1.277, 54.905) = 2.44, P = 0.117) or the IL-6/IL-10 ratio (F(1.874, 80.586) = 0.46, P = 0.620). Compared with the propofol group, the remimazolam group demonstrated significantly higher intraoperative bispectral index (BIS), heart rate, systolic blood pressure, diastolic blood pressure, and mean blood pressure values. Postoperative oxycodone requirements in the post-anesthesia care unit were significantly higher in the propofol group. TNF-α levels remained below the detectable range of the assay and could not be meaningfully analyzed.
conclusionsNo significant intergroup differences were observed in perioperative IL-6 and IL-10 responses between remimazolam and propofol. However, because anesthetic depth may not have been fully equivalent between groups, as reflected by higher BIS values in the remimazolam group, the cytokine and hemodynamic findings should be interpreted cautiously. The absence of statistically significant differences should not be interpreted as evidence of immunologic equivalence between the two anesthetic agents. Further large-scale studies with standardized anesthetic depth are required to clarify the immunomodulatory and hemodynamic effects of remimazolam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.